Ledipasvir
Ledipasvir is a hepatitis C virus NS5A inhibitor represented only with sofosbuvir. Harvoni and Hepcinat LP both carry the complete 90 mg ledipasvir plus 400 mg sofosbuvir tablet identity.
Hepcinat Lp
Chronic Hepatitis C Genotype 1 Infection in Adults
90mg + 400mg
Treats chronic hepatitis C virus infection by inhibiting viral replication, resulting to sustained virological response and elimination of the virus from the body.
Key points
- Ledipasvir blocks an HCV protein needed for viral replication and spread.
- Sofosbuvir is the nucleotide polymerase inhibitor paired with it.
- Both catalogue records use the 90 mg plus 400 mg tablet formulation.
- The combination carries a hepatitis B reactivation warning.
Two antiviral mechanisms in one tablet
Ledipasvir targets the HCV NS5A protein. Sofosbuvir targets the viral polymerase. Their roles explain why the catalogue page is combination-only and why neither Harvoni nor Hepcinat LP is a name for ledipasvir alone.
Both records connect to chronic hepatitis C and sit in hepatitis treatment. Hepcinat LP carries several more detailed genotype and liver-disease labels, but those labels do not change its two-ingredient identity.
Shared strength line
Harvoni and Hepcinat LP each list 90 mg plus 400 mg tablets. The first amount belongs to ledipasvir and the second to sofosbuvir.
Official information warns that hepatitis B can reactivate during or after direct-acting antiviral treatment for hepatitis C. Hepatitis B testing and monitoring are therefore material parts of clinical oversight for this formulation.